<DOC>
	<DOCNO>NCT02727998</DOCNO>
	<brief_summary>The purpose study combine single infusion Ketamine 7-days trauma focus psychotherapy relieve post traumatic stress disorder ( PTSD ) symptoms effectively . This treatment potential produce significant therapeutic effect otherwise would take month occur .</brief_summary>
	<brief_title>Intensive 7-day Treatment PTSD Combining Ketamine With Exposure Therapy</brief_title>
	<detailed_description>Based current research finding therapeutic effectiveness trauma focus psychotherapy ketamine , combine two treatment may yield promise new rapid 7-day treatment PTSD . As PTSD symptom ' structure comprise several unique cluster include re-experiencing , avoidance , numbing/depression hypervigilance investigator hypothesize combine Ketamine prolonged exposure ( PE ) investigator address symptoms cluster effectively . This treatment potential produce significant therapeutic effect otherwise would take month occur tap enhanced neuroplasticity antidepressant effect ketamine ( last 24hrs 7 day ) , promote rapid change learn memory use prolonged exposure therapy within unique `` window opportunity '' . During first visit participant undergo clinical interview establish PTSD diagnosis eligibility criterion . If find eligible participant invite take part 7-day rapid treatment trial PTSD . On first therapy visit , participant educate psychological treatment provide potential benefit ketamine enhance psychotherapy outcome . On second day study , participant receive infusion ketamine undergo magnetic resonance imaging ( MRI ) scan receive second psychotherapy session . On day 3-6 participant attend 60-90 minute psychotherapy session address PTSD symptom . Day 7 include another MRI scan last psychotherapy session . Participants ask come back follow evaluation PTSD symptoms 30 90 day post discharge .</detailed_description>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Male female age 2155 year . This age range choose fit prior sample adverse effect ketamine observe . Adults 1820 range eliminate previous experience indicates often lack maturity participate effectively similar protocol . Females include pregnant agree utilize medically accept birth control method ( include oral , injectable , implant birth control , condom , diaphragm spermicide , intrauterine device , tubal ligation , abstinence , partner vasectomy ) postmenopausal least 1 year , surgically sterile . Able provide write informed consent accord Yale HIC guideline . Able read write English primary language . Diagnosis PTSD , determine Clinician Administered PTSD Scale ( CAPS5 ) ( Weathers et al. , 2013 ) . Must score 50 high ClinicianAdministered PTSD Scale ( CAPS5 ) screening . No mild Traumatic Brain Injury ( TBI ) accord modify version Brief TBI Screen ( Schwab , et al. , 2006 ) . Must medical/neurological problem use medication would render ketamine unsafe history medical evaluation . Patients diagnostic history bipolar disorder , schizophrenia schizoaffective disorder currently exhibit psychotic feature determine Structured Clinical Interview DSM ( SCID ) ( First , et al . 2010 ) ; dementia suspicion thereof , exclude . Other DSM Axis I disorder permit long consider primary disorder . Patients history antidepressantinduced hypomania mania determine openended psychiatric interview . Serious suicide homicide risk , assess evaluate clinician ; A serious suicide risk consider inability control suicide attempt , imminent risk suicide investigator 's judgment , history serious suicidal behavior , define use ColumbiaSuicide Severity Rating Scale ( CSSRS ) ( Posner et al. , 2011 ) either ( 1 ) one actual suicide attempt 3 year study entry lethality rat 3 high , ( 2 ) one interrupt suicide attempt potential lethality judge result serious injury death . Substance abuse dependence 6 month prior screen determine Structured Clinical Interview DSM ( SCID ) . Any significant history serious medical neurological illness . Any sign major medical neurological illness examination result electrocardiogram ( ECG ) screen laboratory study . Lifetime history psychoactive substance alcohol dependence substance alcohol abuse ( nicotine caffeine abuse ) , drink 5 drinks/week last year . Abnormality physical examination . A subject clinical abnormality may include study physician considers abnormality introduce additional risk factor interfere study procedure . A positive prestudy ( screen ) urine drug screen , study physician 's discretion drug screen give scan . Pregnant lactate woman positive urine pregnancy test woman childbearing potential screening prior imaging day . Positive HIV Hepatitis B test . This test take place screen visit . Subjects invite back Yale Depression Research Program either next study visit HIV/Hep debriefing session . A study physician inform person result . They give access counsel advise appropriate next step . Has receive either prescribe overthecounter ( OTC ) centrally active medicine herbal supplement within 60 day enrollment study . Subjects take OTC medication herbal supplement may still enter study , , opinion principal/coinvestigator , medication receive interfere study procedure compromise safety . Any history indicate learn disability , mental retardation , attention deficit disorder . Known sensitivity ketamine . Body circumference 52 inch great . Body weight 250 pound great . History claustrophobia . Presence cardiac pacemaker electronic device ferromagnetic metal foreign body vulnerable position assess standard preMRI screen questionnaire . Donation blood excess 500 mL within 56 day prior dose . History sensitivity heparin heparininduced thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>PTSD</keyword>
</DOC>